News archive
Showing 692 results
April 2017
-
Media Release
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
-- Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)-- R/r DLBCL, an… -
Media Release
Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
March 2017
-
Media Release
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
Priority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T cellsNovartis made an early commitment to the… -
Media Release
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
-
Media Release
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
New post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced… -
Media Release
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
-
Media Release
Novartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
- 94% of patients regained their PASI 75 response and the majority re-achieved their PASI 90 or 100 response after 16 weeks of Cosentyx 300 mg retreatment(1)- Patients may need to pause treatment due… -
Media Release
Novartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
December 2016
-
Media Release
Alcon receives US FDA approval for AcrySof® IQ ReSTOR® +3.0D Multifocal Toric intraocular lens for cataract patients
- New intraocular lens (IOL) combines two technologies that correct for presbyopia and corneal astigmatism simultaneously- This IOL is a new option for patients who desire good near, intermediate and… -
Media Release
Alcon receives US FDA approval for AcrySof® IQ ReSTOR® +3.0D Multifocal Toric intraocular lens for cataract patients
-
Media Release
Novartis out-licenses three COPD products in the US
Sunovion assumes US commercialization rights for Utibron™ Neohaler®, Seebri™ Neohaler® and Arcapta® NeohalerNovartis will continue to manufacture these important medicines for SunovionIn line with… -
Media Release
Novartis out-licenses three COPD products in the US